Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | S-250-002 |
Topic: | Corneal Collagen Cross-Linking and Collagen Crosslinks |
Section: | Surgery |
Effective Date: | May 14, 2018 |
Issue Date: | May 14, 2018 |
Last Reviewed: | September 2017 |
Corneal collagen cross-linking (CXL) is a photochemical procedure for the treatment of progressive keratoconus and corneal ectasia. Keratoconus is a dystrophy of the cornea characterized by progressive deformation (steepening) of the cornea while corneal ectasia is keratoconus that occurs after refractive surgery. Both lead to functional loss of vision and need for corneal transplantation. Collagen crosslinks are biochemical markers which provide a measurement of bone resorption. |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
CXL using riboflavin and ultraviolet A may be considered medically necessary in patients who have failed conservative treatment (e.g., spectacle correction, rigid contact lens) when used for EITHER of the following conditions;
CXL using riboflavin and ultraviolet A is considered experimental/investigational and therefore non-covered for all other indications because of insufficient supporting evidence in peer-reviewed literature.
Collagen crosslinks, any method
Collagen crosslinks, any method, is considered not medically necessary.
Place of Service: Outpatient |
Experimental/Investigational (E/I) services are not covered regardless of place of service.
Corneal Collagen Cross-Linking is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will not be considered medically necessary. A network provider cannot bill the member for the denied service unless: (a) the provider has given advance written notice, informing the member that the service may be deemed not medically necessary; (b) the member is provided with an estimate of the cost; and (c) the member agrees in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |
11/2017: Coverage Criteria Established for Corneal Collagen Cross-Linking